Navigation Links
New target for anti-flu drug development
Date:8/15/2007

Boston, August 15, 2007---Scientists at Cure Lab, Inc., a biotechnology company based in Canton, Massachusetts, in collaboration with researchers at Boston University and Harvard Medical School have discovered a potential new target for the development of anti-influenza (flu) drugs, including those that may be effective against potentially pandemic influenza strains like H5N1.

Their findings have been published in the August 15, 2007 issue of the journal Cell Cycle.

The potential drug target is the flu protein M2, long known to be highly conserved between avian and human strains of the virus. Scientists at Cure Lab found that this M2 protein may single-handedly kill human cells.

This effect may constitute a previously unknown mechanism of influenza virus pathogenicity said Dr. Alex Shneider, senior author on the paper and CEO of the company. If so, drugs that are shown to prevent M2-dependent cell killing have the potential to be used for the treatment of flu.

Membranes covering human and avian cells do not allow ions to move in and out of the cell freely, thus maintaining internal homeostasis. M2 protein of flu virus forms ion channels allowing ion trafficking into cells that cells no longer control. Dr. Shneider and his group not only demonstrated that M2 kills mammalian cells, but also showed that ion channeling through M2 pores may be a molecular mechanism of this cell killing process. Dr. Shneider said that Developing drugs which block M2 ion channels could reduce or eliminate M2-induced cell death, and thus may be a new strategy for targeted development of anti-influenza drugs.

In collaboration with Dr. Vladimir L. Gabai from Boston University, and Dr. Shamil R. Sunyaev from Harvard Medical School scientist from Cure Lab, Inc. have developed mutant forms of M2 protein, where the ion channel is blocked. The researchers have shown that these specific mutations they introduced in the protein significantly reduces its ability to kill the cell. From the point of view of the pharmaceutical industry and feasibility studies, introducing mutations into a protein, which mimic an effect of a future drug, is a way to validate the feasibility of a drug target.

Dr. Shneider said that an M2-targeted search for new anti-influenza drugs could lead to a new generation of medicines which will complement those currently used for influenza disease prevention and treatment. Dr. Petr Ilyinskii, a principal scientist at Cure Lab and the first author on the paper also pointed out that This is especially important since an increasing number of influenza strains are becoming resistant to the drugs that are now widely used.


'/>"/>

Contact: Alex Shneider
thoidis@curelab.com
609-841-1201
Cure Lab, Inc.
Source:Eurekalert

Related biology news :

1. New binding target for oncogenic viral protein
2. Ancient olfaction protein is shared by many bugs, offering new pest control target
3. Novel Enzyme Shows Potential As An Anti-HIV Target
4. A bacterial genome reveals new targets to combat infectious disease
5. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
6. Researchers identify target for cancer drugs
7. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
8. Potential Drug Target For Treating Cocaine Abuse Found
9. Study reveals candidate targets for anti-retroviral therapeutics
10. MUHC researchers make cancer target breakthrough
11. Future diabetes drugs may target new protein interaction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
(Date:3/24/2017)... Controller General of Immigration from Maldives Mr. Mohamed Anwar and ... international IAIR Award for the most innovative high security ePassport and eGates  ... ... Maldives Immigration Controller General, Mr. Mohamed Anwar ... right) have received the IAIR award for the "Most innovative high security ...
Breaking Biology News(10 mins):
(Date:6/22/2017)... ... June 22, 2017 , ... Charm Sciences, Inc. is ... AMPH test was determined to be appropriate as a screening test at dairies and ... the Charm EZ system, and the Charm EZ Lite system. These systems are a ...
(Date:6/20/2017)... ... June 20, 2017 , ... Biologist Dawn Maslar MS has found a biomarker ... Men Chase, Women Choose: The Neuroscience of Meeting, Dating, Losing Your Mind, and Finding ... men. ”The logical next step, in my estimation, was to scientifically track the evidence ...
(Date:6/20/2017)... Pa. , June 20, 2017  Kibow Biotech ... pleased to announce the issuance of a new patent ... or hyperuricemia by the U.S. Patent and Trademark Office ... a winner of the Buzz of Bio award in ... is akin to developing non-drug approaches to chronic disease. ...
(Date:6/20/2017)... ... 2017 , ... Do More with OHAUS , With the launch of the ... the weighing industry, to extending its expertise across the entire laboratory to a range ... more, allowing for its customers to 'Do More' in the lab. , ...
Breaking Biology Technology: